The definition was revised in the 2016 Covered Outpatient Drugs final rule (81 FR 5181 through 5183) and the 2020 Establishing Minimum Standards in Medicaid State Drug Utilization Review and Supporting Value-Based Purchasing for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability Requirements final rule (85 FR 87022 through 87024)
The legal and quality arguments for waiting for the formal reclassification and transitioning to pharmacy-compounded products are strong
In contrast to the Prescriber-Pharmacy Methodology, the Beneficiary-Pharmacy Methodology would identify potentially 340B-eligible units (that would be treated as 340B units for purposes of effectuating the exclusion at 428.203(b)(2)) as units associated with PDE records that are: (1) dispensed by a pharmacy currently under contract with a covered entity, and (2) for beneficiaries who receive care from a covered entity affiliated with that pharmacy
Pentosan is an exciting new treatment, because studies show that it can help heal the subchondral (sub-surface) bone lesions in osteoarthritis and decrease pain
Our advanced NAD+ and bio-optimized wellness products help promote vitality, energy, and long-term well-being through precision science and quality formulations